Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 10:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: clozapine Clear all
Not listed Phase 4 Interventional

Clozapine Versus Olanzapine as Treatment for Comorbid Psychotic Disorder and Substance Use Disorder

NCT03857581
View directory record Official record
Conditions
Psychosis, Substance Use Disorders
Interventions
Clozapine, Olanzapine
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Evans, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 22, 2020 · Synced Sep 25, 2026, 10:58 PM EDT
Completed No phase listed Observational

FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey

NCT00683891
View directory record Official record
Conditions
Weight Gain, Sialorrhea
Interventions
FazaClo (clozapine, USP) ODT
Drug
Lead sponsor
Azur Pharma, Inc
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Costa Mesa, California • Gastonia, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 18, 2008 · Synced Sep 25, 2026, 10:58 PM EDT
Completed Phase 1 Interventional

Reducing Antipsychotic-Induced Weight Gain in Children With Metformin

NCT01231074
View directory record Official record
Conditions
Obesity, Weight Gain, Psychotropic Induced Weight Gain
Interventions
Metformin
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
10 Years to 17 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 1, 2019 · Synced Sep 25, 2026, 10:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clozapine CHAMPION-ECHO Educational Study to Improve Clozapine Use.

NCT04325386
View directory record Official record
Conditions
Schizophrenia Schizoaffective
Interventions
ECHO Intervention, eTAU
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
22 Years to 85 Years
Enrollment
266 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 25, 2026, 10:58 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual

NCT00498550
View directory record Official record
Conditions
Schizophrenia, Dual Diagnosis, Schizoaffective Disorder, Psychotic Disorder, Cannabis Abuse
Interventions
Clozapine, Treatment as usual
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
4
States / cities
Los Angeles, California • Kansas City, Missouri • Manchester, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Sep 25, 2026, 10:58 PM EDT
Completed Not applicable Interventional

Clozapine and Olanzapine Treatment of Aggression

NCT01123408
View directory record Official record
Conditions
Schizophrenia
Interventions
Clozapine, Olanzapine, Haloperidol
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 60 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2010 · Synced Sep 25, 2026, 10:58 PM EDT
Completed Phase 4 Interventional Results available

Clozapine for Cannabis Use in Schizophrenia

NCT01639872
View directory record Official record
Conditions
Schizophrenia, Cannabis Abuse, Cannabis Dependence, Dual Diagnosis
Interventions
Clozapine, Risperidone
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
9
States / cities
Garden Grove, California • Oakland, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 4, 2020 · Synced Sep 25, 2026, 10:58 PM EDT
Terminated Phase 4 Interventional

Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia

NCT00169091
View directory record Official record
Conditions
Schizophrenia
Interventions
Clozapine, Haloperidol
Drug
Lead sponsor
Harvard Medical School (HMS and HSDM)
Other
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Jamaica Plain, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 25, 2026, 10:58 PM EDT
Completed Phase 4 Interventional

Evaluation of Clonazepam and Paroxetine for Panic Disorder With Depression

NCT00031317
View directory record Official record
Conditions
Panic Disorder
Interventions
Paroxetine, Clozapine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 25, 2026, 10:58 PM EDT
Completed Phase 4 Interventional

Risperidone Augmentation in Patients With Schizophrenia

NCT00289861
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Sep 25, 2026, 10:58 PM EDT
Recruiting Phase 4 Interventional

Biomarkers to Enhance Early Schizophrenia Treatment

NCT06969755
View directory record Official record
Conditions
Schizophenia Disorder
Interventions
aripiprazole, risperidone, clozapine
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 35 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
4
States / cities
Birmingham, Alabama • La Jolla, California • Belmont, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 25, 2026, 10:58 PM EDT
Completed Not applicable Interventional Results available

Biomarker and Safety Study of Clozapine in Patients With Benign Ethnic Neutropenia (BEN)

NCT02404155
View directory record Official record
Conditions
Schizophrenia
Interventions
Clozapine
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Sep 25, 2026, 10:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)

NCT03565068
View directory record Official record
Conditions
Schizophrenia
Interventions
MK-8189, Placebo, Background AAP Therapy
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Sep 25, 2026, 10:58 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia

NCT00158223
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Pimozide, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
3
States / cities
New York, New York • W. Brentwood, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2015 · Synced Sep 25, 2026, 10:58 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis

NCT00320671
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole, Risperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Sep 7, 2016 · Synced Sep 25, 2026, 10:58 PM EDT
Completed Phase 4 Interventional Results available

Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients

NCT00176436
View directory record Official record
Conditions
Schizophrenia
Interventions
Diet support group, Group counseling and exercise
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2022 · Synced Sep 25, 2026, 10:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors

NCT00178932
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression
Interventions
genetic analysis, genetic assay
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Sep 25, 2026, 10:58 PM EDT
Terminated No phase listed Observational

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

NCT02893371
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium Carbonate, Lamotrigine, Valproic Acid, Oxcarbazepine, Carbamazepine, Ziprasidone, Risperidone, Quetiapine, Olanzapine, Aripiprazole, Fluoxetine / Olanzapine, Haloperidol, Perphenazine, Clozapine, Asenapine, Lurasidone, Paliperidone, Mirtazapine, Bupropion, Desvenlafaxine, Duloxetine, Venlafaxine, Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Vilazodone, Doxepin
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
Not listed
Enrollment
1,037,352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 25, 2026, 10:58 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia

NCT00345033
View directory record Official record
Conditions
Schizophrenia, Insulin Resistance
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2014 · Synced Sep 25, 2026, 10:58 PM EDT
Terminated Phase 4 Interventional

Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia

NCT00169039
View directory record Official record
Conditions
Schizophrenia
Interventions
Clozapine, Chlorpromazine
Drug
Lead sponsor
Harvard Medical School (HMS and HSDM)
Other
Eligibility
19 Years to 60 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2002
U.S. locations
1
States / cities
Jamaica Plain, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 25, 2026, 10:58 PM EDT
Completed Phase 4 Interventional Results available

Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine

NCT00056498
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Risperdal
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 25, 2026, 10:58 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Pimozide Augmentation for Clozapine Partial Response

NCT00374244
View directory record Official record
Conditions
Schizophrenia
Interventions
Pimozide, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
2
States / cities
New Haven, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Sep 25, 2026, 10:58 PM EDT
Completed Phase 4 Interventional

CATIE- Schizophrenia Trial

NCT00014001
View directory record Official record
Conditions
Schizophrenia
Interventions
perphenazine, olanzapine, quetiapine, risperidone, ziprasidone, clozapine, fluphenazine decanoate
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
54
States / cities
Chula Vista, California • Los Angeles, California • Orange, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2015 · Synced Sep 25, 2026, 10:58 PM EDT
Completed Phase 4 Interventional

Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia

NCT00169065
View directory record Official record
Conditions
Schizophrenia
Interventions
Clozapine, Olanzapine
Drug
Lead sponsor
Harvard Medical School (HMS and HSDM)
Other
Eligibility
20 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Jamaica Plain, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 25, 2026, 10:58 PM EDT